Welcome to our dedicated page for KIORA PHARMACEUTICALS SEC filings (Ticker: KPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiora Pharmaceuticals filings document a clinical-stage ophthalmology issuer focused on small-molecule programs for retinal disease. Current disclosures cover results of operations and financial condition, research-and-development progress for KIO-301 and KIO-104, collaboration reimbursements, and clinical or regulatory updates tied to the company’s development pipeline.
Material-event reports also record securities purchase agreements, common stock, pre-funded warrants and Tranche A warrants issued in private placements, along with executive changes. Proxy materials address board governance, executive compensation, equity awards, shareholder voting matters and related risk-factor disclosures for a Nasdaq-listed Delaware corporation.
Kiora Pharmaceuticals, Inc. is registering for resale up to 11,797,088 shares of Common Stock, consisting of (i) 438,471 shares issued in a private placement, (ii) 1,527,710 shares underlying pre-funded warrants, (iii) 7,864,726 shares underlying Tranche A-1 warrants, and (iv) 1,966,181 shares underlying Tranche A-2 warrants.
The shares are being registered for resale by the selling stockholders named in the prospectus; the company is not offering any shares for its own account and will receive no proceeds from resale transactions, although it will receive proceeds if warrants are exercised for cash. The prospectus notes that the registrable shares represent approximately 72.7% of outstanding common stock as of May 14, 2026 (calculated assuming full exercise of the registered warrants and without applying beneficial ownership limits). Selling holders may sell from time to time by public or private transactions under the plan of distribution described in the prospectus.
Kiora Pharmaceuticals, Inc. is registering 11,797,088 shares of Common Stock for resale by selling stockholders.
The registration covers (i) 438,471 shares issued in a Private Placement, (ii) 1,527,710 shares underlying pre-funded warrants, (iii) 7,864,726 shares underlying Tranche A-1 warrants, and (iv) 1,966,181 shares underlying Tranche A-2 warrants. The Company is not offering any shares for its own account and will receive no proceeds from resales; however, the Company would receive proceeds from any warrant cash exercises. The prospectus states that the registered securities represent approximately 72.7% of outstanding common stock as of May 14, 2026 after giving effect to the registered underlying shares. The resale may occur from time to time through public or private transactions as described in the Plan of Distribution.
Kiora Pharmaceuticals, Inc. reports that Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 438,469 shares of common stock as of March 31, 2026. The filing states those shares represent 9.99% of the outstanding common stock and that the 438,469 shares include shares issuable upon exercise of convertible securities within sixty days. The reporting persons disclose shared voting and dispositive power over the 438,469 shares. A fund advised by Nantahala, BLACKWELL PARTNERS LLC - SERIES A, is identified as having the right to receive dividends or sale proceeds on more than 5% of those shares.
KIORA PHARMACEUTICALS, INC. filing: Alyeska Investment Group and related filers report 394,668 shares beneficially owned, representing 9.99% of Common Stock as of March 31, 2026. The position equals the maximum exercisable under a beneficial ownership limitation tied to warrants.
The filing states the Reporting Persons hold warrants exercisable for 596,854 shares, but the 9.99% limitation permits exercise of only 394,668 shares based on 3,950,628 shares outstanding per the Form 10-K dated March 25, 2026. Voting and investment control is exercised by Alyeska Investment Group, L.P.; Anand Parekh is named but disclaims beneficial ownership.
Kiora Pharmaceuticals reported that Nantahala Capital Partners LP amended its Schedule 13G to state beneficial ownership of 148,736 shares as of March 31, 2026. The filing notes those 148,736 shares include shares acquirable upon exercise of warrants within sixty days. The position represents 3.388% of the class, based on 4,431,940 shares outstanding as of the 10-Q filed May 8, 2026.
Kiora Pharmaceuticals reported first quarter 2026 results, highlighting clinical progress in its retinal disease pipeline and a modestly higher net loss. The company recorded a net loss of $2.4 million for the quarter, or $0.58 per basic and diluted share.
Kiora ended March 31, 2026 with $13.9 million in cash and short-term investments and subsequently raised an additional $5.0 million through a strategic equity financing. Management believes this supports an operational runway into late 2028, beyond anticipated data readouts from its KIO-301 ABACUS-2 and KIO-104 KLARITY Phase 2 trials.
Enrollment in ABACUS-2 for KIO-301 is roughly half complete, supported by strong patient demand and expanded trial sites, and prior ABACUS-1 data were published in Nature Medicine. KIO-104 continues in the KLARITY study, with a planned safety review expected to enable escalation to a higher dose cohort.
Kiora Pharmaceuticals, Inc. reported a net loss of $2.4 million for the three months ended March 31, 2026, compared with $2.2 million a year earlier, as it continues investing in ophthalmic drug development.
Total operating expenses were $2.5 million, including $1.6 million in general and administrative costs and $2.1 million in research and development, partly offset by $1.2 million of collaboration credits tied to the KIO‑301 program. Other income, mainly interest, added $0.1 million.
At March 31, 2026, Kiora held $11.0 million in cash and cash equivalents and $2.9 million in short‑term investments, with total assets of $21.2 million and stockholders’ equity of $13.9 million. Management states that, including $5 million raised in an April 2026 private placement and reimbursement of all KIO‑301 expenses by partner Théa Open Innovation, current resources are expected to fund planned operations into late 2028.
Kiora Pharmaceuticals is asking stockholders to vote at its 2026 annual meeting on director elections, executive pay, auditor ratification, and an equity plan increase. Three Class II directors are nominated to serve until 2029. Investors will cast a non-binding advisory vote on 2025 compensation for the CEO and other named executives, and on retaining Haskell & White LLP as independent auditor for 2026. The company also seeks approval to amend its 2024 Equity Incentive Plan to add 1,500,000 shares for future equity awards. As of the April 16, 2026 record date, 4,432,440 common shares were outstanding, each with one vote.